Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes
2015-02-20 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 20 February 2015 - Novo Nordisk today announced that it has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks. Further information Media: Mike Rulis +45 3079 3573 [email protected] Investors: Kasper Roseeuw Poulsen +45 3079 4303 [email protected] Jannick Lindegaard Denholt +45 3079 8519 [email protected] Daniel Bohsen +45 3079 6376 [email protected] Melanie Raouzeos +45 3075 3479 [email protected] Frank Daniel Mersebach (US) +1 609 235 8567 [email protected] Company announcement No 14 / 2015
The release as fetched from its publisher. novonordisk.com ↗